source
- GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancerGSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...Endpoints · 35m ago↗ source
- On eve of Senate committee vote, Trump's FDA pick hasn't locked up confirmationOn Wednesday, the Trump administration's pick to lead the FDA will face a key vote in the Senate. Whether she'll pass or fail may go down to the wire. Less than 24 hours before the ...Endpoints · 36m ago↗ source
- Lilly pens another deal, inking up to $5.9B oncology pact with StippleA licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.